NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack

Journal of Biological Chemistry

Volumn 289, Issue 5, 2014, Pages 2711-2724

  Du, Yiqun ^a   Teng, Xiaoyan ^a,b   Wang, Na ^a   Zhang, Xin ^a   Chen, Jianfeng ^a   Ding, Peipei ^a   Qiao, Qian ^a   Wang, Qingkai ^a   Zhang, Long ^a   Yang, Chaoqun ^c   Yang, Zhangmin ^b   Chu, Yiwei ^a   Du, Xiang ^d   Zhou, Xuhui ^c   Hu, Weiguo ^a  

^a FUDAN UNIVERSITY   (China)

^b SHAANXI NORMAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT ACTIVATIONS; CONSTITUTIVE EXPRESSIONS; CREB BINDING PROTEINS; ENHANCER-BINDING PROTEINS; IMMUNE SURVEILLANCE; INDUCIBLE EXPRESSION; MEMBRANE ATTACK COMPLEXES; POTENTIAL DRUG TARGETS;

CHEMICAL ACTIVATION;

PROTEINS;

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD59 GENE; CELL PROTECTION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; GENE; GENE CONTROL; HOST RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION;

CBP; COMPLEMENT SYSTEM; CREB; NF-ΚB (NF-KB); P300;

ANTIGENS, CD59; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CREB-BINDING PROTEIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; ENHANCER ELEMENTS, GENETIC; HELA CELLS; HUMANS; LIPOPOLYSACCHARIDES; NF-KAPPA B; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; U937 CELLS;

EID: 84893481717     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.525501     Document Type: Article

References (48)

1. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Complement. A key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797
2. Morgan, B. P., Marchbank, K. J., Longhi, M. P., Harris, C. L., and Gallimore, A. M. (2005) Complement. Central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97, 171-179
3. Meri, S., Waldmann, H., and Lachmann, P. J. (1991) Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65, 532-537
4. Ruiz-Argüelles, A., and Llorente, L. (2007) The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun. Rev. 6, 155-161
5. Song, W. C (2006) Complement regulatory proteins and autoimmunity. Autoimmunity 39, 403-410
6. Rus, H. G., Niculescu, F. I., and Shin, M. L. (2001) Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol. Rev. 180, 49-55
7. Holguin, M. H., Martin, C. B., Eggett, T., and Parker, C. J. (1996) Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. J. Immunol. 157, 1659-1668
8. Donev, R. M., Cole, D. S., Sivasankar, B., Hughes, T. R., and Morgan, B. P. (2006) p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res. 66, 2451-2458
9. Cui, W., Zhao, Y., Shan, C, Kong, G., Hu, N., Zhang, Y., Zhang, S., Zhang, W., Zhang, Y., Zhang, X., and Ye, L. (2012) HBXIP up-regulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack. FEBS Lett. 586, 766-771
10. Tone, M., Diamond, L. E., Walsh, L. A., Tone, Y., Thompson, S. A., Shanahan, E. M., Logan, J. S., and Waldmann, H. (1999) High level transcription of the complement regulatory protein CD59 requires an enhancer located in intron 1. J. Biol. Chem. 274, 710-716
11. Tan, N. Y., and Khachigian, L. M. (2009) Sp1 phosphorylation and its regulation of gene transcription. Mol. Cell Biol. 29, 2483-2488
12. Bouwman, P., and Philipsen, S. (2002) Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 195, 27-38
13. Bonizzi, G., and Karin, M. (2004) The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288
14. Mayr, B., and Montminy, M. (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2, 599-609
15. Gonzalez, G. A., and Montminy, M. R. (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680
16. Goodman, R. H, and Smolik, S. (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577
17. Chan, H. M., and La Thangue, N. B. (2001) p300/CBP proteins. HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114, 2363-2373
18. Sampaziotis, F., Kokotas, S., and Gorgoulis, V. G. (2002) p53 possibly up-regulates the expression of CD58 (LFA-3) and CD59 (MIRL). Med. Hypotheses 58, 136-140
19. Wesche-Soldato, D. E., Swan, R. Z., Chung, C. S., and Ayala, A. (2007) The apoptotic pathway as a therapeutic target in sepsis. Curr. Drug Targets 8, 493-500
20. Attali, G., Gancz, D., and Fishelson, Z. (2004) Increased sensitivity of early apoptotic cells to complement-mediated lysis. Eur. J. Immunol. 34, 3236-3245
21. Manderson, A. P., Pickering, M. C, Botto, M., Walport, M. J., and Parish, C. R. (2001) Continual low-level activation of the classical complement pathway. J. Exp. Med. 194, 747-756
22. Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., and Kinoshita, T. (1993) Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73, 703-711
23. Nevo, Y., Ben-Zeev, B., Tabib, A., Straussberg, R., Anikster, Y., Shorer, Z., Fattal-Valevski, A., Ta-Shma, A., Aharoni, S., Rabie, M., Zenvirt, S., Goldshmidt, H., Fellig, Y., Shaag, A., Mevorach, D., and Elpeleg, O. (2013) CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121, 129-135
24. Aiyaz, M., Lupton, M. K., Proitsi, P., Powell, J. F., and Lovestone, S. (2012) Complement activation as abiomarker for Alzheimer's disease. Immunobiology 217, 204-215
25. McGeer, P. L., Walker, D. G., Akiyama, H., Kawamata, T., Guan, A. L., Parker, C. J., Okada, N., and McGeer, E. G. (1991) Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544, 315-319
26. Zanjani, H., Finch, C. E., Kemper, C., Atkinson, J., McKeel, D., Morris, J. C., and Price, J. L. (2005) Complement activation in very early Alzheimer disease. Alzheimer Dis. Assoc Disord 19, 55-66
27. Yang, L. B., Li, R., Meri, S., Rogers, J., and Shen, Y. (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20, 7505-7509
28. Mattson, M. P., and Meffert, M. K. (2006) Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ 13, 852-860
29. Saura, C. A., and Valero, J. (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev. Neurosci. 22, 153-169
30. Barros, M. M., Yamamoto, M., Figueiredo, M. S., Cançado, R., Kimura, E. Y., Langhi, D. M., Jr., Chiattone, C. S., and Bordin, J. O. (2009) Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signalregulatory protein-a, β on monocytes from patients with warm autoimmune hemolytic anemia. Transfusion 49, 154-160
31. Dale, E., Davis, M., and Faustman, D. L. (2006) A role for transcription factor NF-κB in autoimmunity. Possible interactions of genes, sex, and the immune response. Adv. Physiol. Educ. 30, 152-158
32. Wu, G., Hu, W., Shahsafaei, A., Song, W., Dobarro, M., Sukhova, G. K., Bronson, R. R., Shi, G. P., Rother, R. P., Halperin, J. A., and Qin, X. (2009) Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 104, 550-558
33. Ross, R. (1993) The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 362, 801-809
34. Amet, T., Ghabril, M., Chalasani, N, Byrd, D., Hu, N, Grantham, A., Liu, Z., Qin, X., He, J. J., and Yu, Q. (2012) CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology 55, 354-363
35. Schmitz, J., Zimmer, J. P., Kluxen, B., Aries, S., Bögel, M., Gigli, I., and Schmitz, H. (1995) Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J. Clin. Invest. 96, 1520-1526
36. Schottenfeld, D., and Beebe-Dimmer, J. (2006) Chronic inflammation. A common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 56, 69-83
37. Koch, N, Jung, M., Sabat, R., Krätzschmar, J., Döcke, W. D., Asadullah, K., Volk, H. D., and Grütz, G. (2009) IL-10 protects monocytes and macrophages from complement-mediated lysis. J. Leukoc. Biol. 86, 155-166
38. Spiller, O. B., Criado-García, O., Rodríguez De Córdoba, S., and Morgan, B. P. (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121, 234-241
39. Gemei, M., Di Noto, R., Mirabelli, P., and Del Vecchio, L. (2013) Cytometric profiling of CD133+ cells in human colon carcinoma cell lines identifies a common core phenotype and cell type-specific mosaics. Int. J. Biol. Markers 28, 267-273
40. Zhu, J., Nie, S., Wu, J., and Lubman, D. M. (2013) Target Proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immunolaser capture microdissection and nano-LC-MS/MS. J. Proteome Res. 12, 2791-2804
41. Li, B., Chu, X., Gao, M., and Xu, Y. (2011) The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol. 272, 61-70
42. Langer, H. F., Chung, K. J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., De Angelis, R. A., Roche, P. A., Magotti, P., Li, X., Economopoulou, M., Rafail, S., Lambris, J. D., and Chavakis, T. (2010) Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116, 4395-4403
43. Fishelson, Z., Donin, N, Zell, S., Schultz, S., and Kirschfink, M. (2003) Obstacles to cancer immunotherapy. Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40, 109-123
44. Rayet, B., and Gélinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947
45. Siu, Y. T., and Jin, D. Y. (2007) CREB. A real culprit in oncogenesis. FEBS J. 274, 3224-3232
46. Safe, S., and Abdelrahim, M. (2005) Sp transcription factor family and its role in cancer. Eur. J. Cancer 41, 2438-2448
47. Baud, V., and Karin, M. (2009) Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev. Drug Discov. 8, 33-40
48. Conkright, M. D., and Montminy, M. (2005) CREB. Theunindicted cancer co-conspirator. Trends Cell Biol. 15, 457-459